celgene's revlimid extends life in cancer trial
celgene corp's cancer drug, revlimid, significantly extended the lives of patients with multiple myeloma who took the drug as a maintenance therapy following a stem cell transplant.
http://feeds.reuters.com/~r/reuters/healthnews/~3/qc0b8tvbd0a/us-celgene-idustre7444x120110505
1998
05 May 2011 19:50:23
reuters
health